While brachytherapy improved progression-free survival in men with prostate cancer, compared with traditional readiotherapy, the study found that overall survival was not very different between the 2 groups.
A prostate cancer treatment using permanently implanted radioactive “seeds” doubles rates of 5-year tumour-free survival compared with conventional high-dose radiotherapy, a study has found.
Low-dose-rate prostate brachytherapy (LDR-PB) involves the insertion of tiny radioactive implants into the prostate gland. A trial comparing the treatment with dose-escalated external beam radiotherapy found that it was much more successful at banishing cancer. Men who underwent LDR-PB were twice as likely to be cancer-free 5 years later. Scientists studied 398 men with cancer that had not spread outside the prostate gland who were judged to be at high risk of treatment failure based on standard test results.
Lead researcher Professor James Morris, from Vancouver Cancer Centre in Canada, said: “At five years follow-up, we saw a large advantage in progression-free survival in the LDR-PB group.
Link to the complete article on The Guardian: http://bit.ly/1EciTDF
Children With AD, Neurodevelopmental Comorbidities at Greater Odds of Learning, Memory Difficulties
March 18th 2024Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.
Read More
Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF
March 16th 2024New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Read More